We investigated the safety and efficacy of simeprevir with peg-interferon -2 a and ribavirin ( PR ) in a randomized , double-blind , placebo-controlled , phase 3 trial of patients with HCV genotype 1 infection who relapsed after previous interferon-based therapy .